Cambridge Innovation Institute has acquired Neurotech Reports, the neurotechnology sector’s longest-running independent trade publication, the companies announced on March 23. Financial terms were not disclosed.
Neurotech Reports was founded in 2001 by James Cavuoto, a biomedical engineer who studied functional electrical stimulation at Case Western Reserve University before spending three years at Hughes Aircraft Company working on simulation products for the US Department of Defense. Over 25 years he built the publication into the primary source of market research and commercial intelligence for the neurotechnology industry, producing annual market reports, newsletters, and the Neurotech Leaders Forum conference series.
Cavuoto will remain as editor and publisher under CII’s umbrella. JoJo Platt, a contributing editor and general manager with over 15 years in neurotechnology who played a central role in launching the field of bioelectronic medicine, and Jeremy Koff, a senior consulting editor with two decades of medical device experience across roughly 20 neuromodulation companies, will also stay on.
“Our 25-year history of covering scientific and commercial news and events combined with CII’s demonstrated quality and integrity are a natural partnership,” Cavuoto said in a statement.
CII, founded in 1992 and based in Needham, Massachusetts, operates three divisions spanning life sciences, energy, and executive events. Its Cambridge Healthtech Institute arm runs conferences and publishes research for pharmaceutical and biotech organisations. The Neurotech Reports acquisition slots into the company’s Cambridge VIP division, which focuses on executive-level events and venture acceleration.
“The neurotech field within healthcare continues to grow and will benefit from additional advancement via opportunities for knowledge sharing, fundraising, and collaboration,” said CII chief executive Benjamin Lakin.
The first event under the combined organisation will be the ninth annual Bioelectronic Medicine Forum on April 14 at the New York Academy of Medicine. Michel Maharbiz, the UC Berkeley professor who founded iota Biosciences (acquired by Astellas in 2021), will deliver the keynote. The programme includes panels on novel diagnostics, emerging technologies, reimbursement policy, and a venture capital session featuring investors from Features Capital, ATEM Capital, and Ladenburg Thalmann.
The acquisition arrives at a moment when the neurotechnology sector is outgrowing the infrastructure that once served it. The worldwide neurotech market is projected to reach $17.1 billion in 2026, according to Neurotech Reports’ own estimates. Over $400 million in new funding was recorded in the first half of March alone, with large rounds going to Science Corp and Cognito alongside continued activity in implanted pain management, prosthetics, and brain-computer interfaces. Patent filings and acquisitions by major technology companies suggest mainstream commercial interest is accelerating.
For a field that spent decades as a niche corner of medical devices, the deal is a small but telling signal. An independent newsletter that once had the space largely to itself is now part of a conference and media group that sees neurotechnology as a growth market worth building around.